NASDAQ:CDT

CDT Equity Q1 2026 Earnings Results & Report

CDT Equity logo
$0.34 -0.03 (-8.49%)
As of 03:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CDT Equity reported Q1 2026 earnings on July 15, 2026. The company reported EPS of -$27,800.00.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

CDT Equity EPS Results

Actual EPS
-$27,800.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CDT Equity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CDT Equity Q1 2026 Earnings FAQ

CDT Equity (NASDAQ:CDT) reported earnings of -$27,800.00 per share for Q1 2026. The report was announced on Wednesday, July 15, 2026.

CDT Equity Earnings Headlines

Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
CDT Equity Announces 1-for-20 Reverse Stock Split
See More CDT Equity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email.

About CDT Equity

CDT Equity (NASDAQ:CDT) (NASDAQ: CDT) is associated with the former Conduit Pharmaceuticals, a biotechnology company focused on developing drug candidates for diseases with unmet medical needs.

Conduit’s historical pipeline included compounds licensed from AstraZeneca, with research directed toward areas including inflammation and autoimmune disease. The company’s approach was to advance existing drug candidates rather than discover medicines entirely from scratch.

Conduit had operations and a corporate presence in the United Kingdom and the United States. Because the company’s name and business status have changed, its historical biotechnology activities may not fully describe CDT Equity’s current operations.

View CDT Equity Profile